Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/15/2007US20070265291 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid; allergic disease; systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch
11/15/2007US20070265290 Male contraceptices; hormone sensitivity diseases; antidepressants; sexual disorders ; osteoporosis; alopecia; prostate cancer
11/15/2007US20070265289 2-Aminopyrimidine Derivative
11/15/2007US20070265288 Stable Crystal Form of Imatinib Mesylate and Process for the Preparation Thereof
11/15/2007US20070265287 Method for Producing 2-Amino-4,6-Dichloro-5-Formamidopyrimidine
11/15/2007US20070265286 Quinazoline derivatives as VEGF inhibitors
11/15/2007US20070265285 Quinazolinone derivatives and their use as CB agonists
11/15/2007US20070265284 Substituted 8-aminoalkylthioxanthines, and their use as inhibitors of dipeptidyl peptidase iv
11/15/2007US20070265283 Xanthine Oxidase Inhibitor
11/15/2007US20070265282 Use of ticagrelor treating myocardial infarction, thrombotic stroke, angina and transient ischemic attacks
11/15/2007US20070265281 Organic Compounds and Their Uses
11/15/2007US20070265280 Methods of using sodium channel blockers
11/15/2007US20070265279 Use of mGluR5 antagonists for the treatment of pruritic conditions
11/15/2007US20070265278 2-phenyl-indoles as prostaglandin d2 receptor antagonists
11/15/2007US20070265277 Serotonin 5-Ht3 Receptor Agonist
11/15/2007US20070265276 Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders
11/15/2007US20070265275 Treatment of Mastitis
11/15/2007US20070265274 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
11/15/2007US20070265273 Pyrimidin-2-Amine Derivatives and Their Use as A2b Adenosine Receptor Antagonists
11/15/2007US20070265272 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol, for example; for treating hyperproliferative disorders
11/15/2007US20070265271 (8-Methyl-3,8-diaza-bicyclo[3.2.1]oct-3-yl)-[5-(4-nitro-phenyl)-furan-2-yl]-methanone; cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters; nervous system diseases; inflammation, pain; drug addiction
11/15/2007US20070265270 Cinnoline derivatives as phosphodiesterase 10 inhibitors
11/15/2007US20070265269 Water Soluble Esters of [N-(4-Amino-2-Butynyl)] with Anticancer Activity
11/15/2007US20070265268 inhibiting heat shock protein 90 (Hsp90) family protein comprising administering benzoic acid derivatives or prodrugs, for the treatment of breast cancer or leukemia
11/15/2007US20070265265 Such as 2-{4-[4-(Cyclopentanecarbonyl-amino)-phenyl]-thiazol-2-ylcarbamoyl}-pyrrolidine-1-carboxylic acid benzyl ester; Flaviviruses
11/15/2007US20070265264 Thia-tetraazaacenaphthylene kinase inhibitors
11/15/2007US20070265263 Heterocyclic inhibitors of ERK2 and uses thereof
11/15/2007US20070265262 viricides selecting from a group of compounds, carbamoyl-pyrrolidine-1-carboxylic acid benzyl ester derivatives; treating or preventing a viral infection; 2-(2',4'-Dimethoxy-biphenyl-4-ylcarbamoyl)-pyrrolidine-1-carboxylic acid benzyl ester
11/15/2007US20070265261 Dpp-IV Inhibitors
11/15/2007US20070265260 Quinazoline derivatives
11/15/2007US20070265259 Proline Derivatives
11/15/2007US20070265258 Quinazoline derivatives as phosphodiesterase 10 inhibitors
11/15/2007US20070265257 Morpholine Compound
11/15/2007US20070265256 Phosphodiesterase 10 inhibitors
11/15/2007US20070265255 use in catalytic enantioselective alkynylation and alkylation of a range of aromatic and aliphatic aldehydes, generating chiral propargylic alcohols and secondary alcohols in high yields and enantiomeric excess
11/15/2007US20070265254 Naphthaline derivatives as H3 inverse agonists
11/15/2007US20070265253 non-steroidal antiinflammatory agents such as 4H-Pyrido[2,3-g][1,4]benzothiazine-5,10-dione-1,1-dioxo-7-carboxylic acid, useful for treating inflammatory diseases or disorders
11/15/2007US20070265252 modulator of cholesteryl ester transfer protein (CETP), such as 1,1,1-Trifluoro-3-[3-[3-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-8-(3-trifluoromethoxy-phenyl)-2,3-dihydro-benzo[1,4]oxazin-4-yl]-propan-2-ol, used for treating cardiovascular disorders, dyslipidemia, and metabolic disorders
11/15/2007US20070265251 Muscarinic Antagonists With Parp and Sir Modulating Activity as Cytoprotective Agents
11/15/2007US20070265250 Imidazole compounds
11/15/2007US20070265249 Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction
11/15/2007US20070265248 Substituted piperazines and methods of use
11/15/2007US20070265247 Method of reducing contact lens intolerance with non-drying antihistamines
11/15/2007US20070265246 Treatment of an Intestinal Adenoma and/or Adenocarcinoma by Inhibition of Notch Pathway Activation
11/15/2007US20070265245 S-Mirtazapine For The Treatment Of Hot Flush
11/15/2007US20070265244 2-[1-(1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylcarbamoyl)-cyclopentylmethyl]-N-(3-dimethylamino-propyl)-N-methyl-succinamic acid, or a biolabile ester thereof; neutral endopeptidase and/or human soluble endopeptidase (hSEP) inhibitors; cardiovascular diseases, apoptosis e.g. stroke
11/15/2007US20070265243 Antibiotic-Bound Poly(Caprolactone) Polymer
11/15/2007US20070265242 Novel Carbapenem Compound
11/15/2007US20070265241 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
11/15/2007US20070265240 Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes
11/15/2007US20070265239 Topically applicable anti-inflammatory O/W emulsions comprising pro-penetrating glycols
11/15/2007US20070265238 Method for accelerating reentrainment of a circadian rhythm
11/15/2007US20070265237 Pure rocuronium bromide
11/15/2007US20070265236 Asthma Treatment Methods
11/15/2007US20070265235 Methods for treating or preventing disorders using ecdysteroid compositions
11/15/2007US20070265234 Methods for stabilizing oxidatively unstable compositions
11/15/2007US20070265233 Arginine Heteromers for Topical Administration
11/15/2007US20070265232 Administering balsalazide with food increases bioavailability of balsalazide and metabolites 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid; label on container recommends to take drug with food; inflammatory bowel disease, radiation enteritis, colon cancer; gastrointestinal disorders
11/15/2007US20070265230 Radiopharmaceuticals For Diagnosis And Therapy
11/15/2007US20070265228 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis
11/15/2007US20070265227 Inhibition of hiv infection fhrough chemoprophyalxis
11/15/2007US20070265226 Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use
11/15/2007US20070265225 Substituted monocyclic CGRP receptor antagonists
11/15/2007US20070265224 Nucleotide mimics and their prodrugs
11/15/2007US20070265223 Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions
11/15/2007US20070265222 Nucleoside Aryl Phosphoramidates for the Treatment of Rna-Dependent Rna Viral Infection
11/15/2007US20070265221 Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure
11/15/2007US20070265219 Modulation of thyroid hormone receptor interactor 3 expression
11/15/2007US20070265218 Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
11/15/2007US20070265217 Single Nucleotide Polymorphisms as Prognostic Tool to Diagnose Adverse Drug Reactions (Adr) and Drug Efficacy
11/15/2007US20070265216 Enhanced medical treatment in diabetic cardiomyopathy
11/15/2007US20070265214 Antisense antiviral agent and method for treating ssRNA viral infection
11/15/2007US20070265213 Use of Docetaxel/Doxorubicin/Cyclophosphamide in Adjuvant Therapy
11/15/2007US20070265212 Drug Transport and Delivery System
11/15/2007US20070265211 Novel composition and method effective in inhibiting the atherogenic process
11/15/2007US20070265210 Administration of C-glycoside compounds for protecting and/or activating gammadeltaT lymphocytes
11/15/2007US20070265209 Cosmetic or pharmaceutical oil-in-water emulsion
11/15/2007US20070265208 Association of calpain inhibitors and reactive oxygen species trapping agents
11/15/2007US20070265202 Compounds That Modulate Trh Actions
11/15/2007US20070265196 Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein
11/15/2007US20070265194 Agents for the treatment of viral infections
11/15/2007US20070265193 Tetraazabenzo[e]azulene derivatives and analogs thereof
11/15/2007US20070265191 Pharmaceutical compositions and methods for peptide treatment
11/15/2007US20070265188 LDL Receptor-Related Proteins 1 and 2 and Treatment of Bone or Cartilage Conditions
11/15/2007US20070265185 Phosphorylated Vimentin Serving as a Marker of the Aggressiveness and/or Invasiveness of Tumors
11/15/2007US20070264417 Procyanidins; cleaning cocoa beans, heating unroasted cocoa nibs to loosen shells, winnowing the nibs from the shells, extracting with a polar solvent, a non-polar solvent, or a supercritical fluid
11/15/2007US20070264362 Method and composition for treating ear inflammation caused by dry ear
11/15/2007US20070264360 Gall bladder and liver cleansing suppository
11/15/2007US20070264359 administering an effective amount of an aqueous or alcohol extract of Phyllanthus to a mammal infected with the YMDD hepatitis B virus mutant strain resistant; inhibiting viral gene expression in a mammal infected with a hepatitis B virus
11/15/2007US20070264358 Methods and Compositions for Treating Mood Disorder
11/15/2007US20070264354 Treatment of a wound with a vasodilator
11/15/2007US20070264351 Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
11/15/2007US20070264350 Water-insoluble medicine
11/15/2007US20070264349 Nano-structured compositions and methods of making and using the same
11/15/2007US20070264348 Nanoparticulate fibrate formulations
11/15/2007US20070264345 liquid crystal gel containing polyoxyethylene-glyceryl-trioleate, 26.7-40.0%, propylene-glycol, 13.3-20.0%, isopropyl myristate, 5.0-35.0%, ethanol, 0.01-10.0%, benzyl alcohol, 0.5-1.5%, a hyaluronic acid salt or complex 0.01-2.00%, and purified water, 12.5-26.5%; healing cosmetics
11/15/2007US20070264343 Methods for making and using particulate pharmaceutical formulations for sustained release
11/15/2007US20070264339 Base-stabilized polyorthoester formulations
11/15/2007US20070264338 Base-stabilized polyorthoester formulations
11/15/2007US20070264337 Compositions and methods for the induction and maintenance of quality sleep
1 ... 3501 3502 3503 3504 3505 3506 3507 3508 3509 3510 3511 3512 3513 3514 3515 3516 3517 3518 3519 3520 3521 ... 7860